Neurocrine biosciences announces first-patient dosed in phase 2 clinical study evaluating nbi-1070770 in adults with major depressive disorder

San diego , april 3, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that the first patient has been randomized for its phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound nbi-1070770 in adults with major depressive disorder. nbi-1070770 is a novel, selective, and orally active, negative allosteric modulator (nam) of the nr2b subunit-containing n-methyl-d-aspartate (nmda nr2b) receptor.
NBIX Ratings Summary
NBIX Quant Ranking